Investing.com - Financial Markets Worldwide

PharmaTher receives FDA approval for ketamine product KETARx

Published 11/08/2025, 14:58
PharmaTher receives FDA approval for ketamine product KETARx
PHRRF
19.31%

TORONTO - PharmaTher Holdings Ltd. (OTCQB:PHRRF) (CSE:PHRM) received U.S. Food and Drug Administration approval for its ketamine product KETARx on Friday for surgical pain management applications, the company announced Monday. The stock, currently valued at $33.09 million in market capitalization, has seen remarkable momentum with a 148% price return over the past six months, according to InvestingPro data.

The approval represents a significant milestone for the specialty pharmaceutical company, which focuses on developing ketamine-based treatments.

"With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals," said Fabio Chianelli, Founder, Chairman and CEO of PharmaTher, in a press release statement.

Ketamine is included on the World Health Organization’s Model List of Essential Medicines. The global ketamine market is currently valued at $750 million and projected to reach $3.42 billion by 2034, representing a compound annual growth rate of 16.4%.

The FDA approval provides a foundation for PharmaTher to expand development of ketamine across various therapeutic areas within its product pipeline, including depression, Parkinson’s disease, Amyotrophic Lateral Sclerosis, and complex pain conditions. While the company is not yet profitable, investors seeking detailed analysis of PharmaTher’s growth potential can access comprehensive financial metrics and expert insights through InvestingPro.

Since February 2018, ketamine has been regularly listed on the FDA drug shortage list. In October 2023, the FDA issued a compounding risk alert detailing potential risks associated with compounded ketamine products used for psychiatric disorders.

The Veterans Health Administration currently approves and funds ketamine infusions for retired military personnel with depression, PTSD, and chronic pain, according to the company’s statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.